Listing 1 - 10 of 22 | << page >> |
Sort by
|
Choose an application
Choose an application
Choose an application
Choose an application
Choose an application
Obesity has become a major health problem for modern Western-type societies. The worldwide prevalence of obesity has doubled since the 1980’s and today over 600 million adults are obese. Moreover, obesity is associated with the development of chronic diseases such as type 2 diabetes, cardiovascular diseases and fatty liver disease. This presents a heavy burden to the health care sector and has major economical consequences. However, efficient therapies to achieve metabolic health are not readily available.Adipose tissue has played an essential role in the adaptation of humans during evolution, i.e to food scarcity and cold. On the one hand, white adipose tissue is programmed to store excess energy in the form of triglycerides. On the other hand, brown adipose tissue efficiently burns energy to produce heat (thermogenesis). Over the last decade a third type of adipocyte was identified, namely the beige adipocyte. This adipocyte is mainly found in subcutaneous adipose tissue and is bi-functional, meaning that it can adapt to energy storage or to thermogenesis, depending on the metabolic need. A good understanding of adipose tissue biology is necessary for the development of new therapeutic strategies against obesity. Adipose tissue expansion consists of hypertrophy (existing adipocytes increase in volume), hyperplasia (new adipocytes arise from precursor cells), angiogenesis (formation of new blood vessels) and remodeling of the extracellular matrix. The metalloproteinase family is involved in all of these processes. This superfamily can be further divided into several subfamilies including the MMP (matrix metalloproteinases) family. A potential role for MMP-2 and MMP-9 was reported in obesity, although many discrepant results were presented. In the present study, we further investigated the specific roles of MMP-2 and MMP-9 in adipogenesis in vitro. Therefore, we used established in vitro models:- murine embryonic fibroblasts (MEF) derived from wild-type and gene deficient mice were stimulated towards adipogenic differentiation.- 3T3-F442A preadipocytes were differentiated into mature adipocytes, while MMP levels were modulated by genetic knockdown (shRNA-mediated) or overexpression.In agreement with diet studies performed on mice with genetic deficiencies, we demonstrated that MMP-2 but not MMP-9 is an important player in preadipocyte differentiation.Another subfamily of the metalloproteinases is the ADAMTS (A disintegrin and metalloproteinase with thrombospondin type 1 motifs) family. Relatively little is known on the role of this subfamily in adipose tissue development, although it has been reported that several members, including ADAMTS5, are upregulated in adipose tissue of obese mice. We studied the effects of ADAMTS5 on adipogenesis both in vitro and in vivo, and on adipose tissue development in nutritionally-induced obesity in mice. Using 3T3-F442A cells and MEFs, we demonstrated that ADAMTS5 promotes adipogenesis in vitro, and also stimulates de novo adipogenesis in vivo. Moreover, mice with genetic ADAMTS5 deficiency, kept on a high fat diet, developed less visceral adipose tissue mass and were protected against liver steatosis. This hepatic phenotype appears to be due to reduced uptake of triglycerides from the circulation into the liver, thereby protecting liver integrity. It is tempting to speculate that neutralization of ADAMTS5 may protect against diet-induced steatohepatitis.Surprisingly, we also observed an increased mass of brown adipose tissue in ADAMTS5 deficient mice. Moreover, in subcutaneous white adipose tissue of ADAMTS5 deficient as compared to wild-type mice, more beige adipocytes were observed (also known as ‘browning’). The brown adipose tissue was shown to be metabolically active, but only small differences in heat production and energy expenditure were observed, without significant effects of ADAMTS deficiency on total body weight. Furthermore, browning of white adipose tissue was strongly enhanced upon exposure to cold, a known stimulator. These findings indicate that ADAMTS5 plays an important functional role in development of white and brown adipose tissue. It remains to be shown whether neutralization of ADAMTS5 is a viable strategy to enhance thermogenesis and to reduce obesity.
Choose an application
Choose an application
Choose an application
In this PhD project, we have studied the role of the host hemostatic system and its manipulation by S. aureus in the outcome of S. aureus infections.It has long been known that most S. aureus strains produce staphylokinase. We have shown that staphylokinase-mediated fibrinolytic and proteolytic activity permit the local invasion of S. aureus in skin and soft tissue through degradation of fibrin and extracellular matrix. The fibrin-specificity of staphylokinase limits its action to the vicinity of the fibrin-rich S. aureus abscess community, as both fibrin and bacterial surfaces protect staphylokinase from inhibition by alpha-2-antiplasmin. Indeed, the host protease inhibitor alpha-2-antiplasmin limited bacterial dissemination in later stages of skin infection. (Chapter 1, Research Question 1)Fibrin is a central component of S. aureus biofilms in foreign body infections, such as catheter infections. We have shown that staphylokinase production is downregulated inside biofilms, but quorum sensing dependent upregulation of staphylokinase allows S. aureus to escape from its fibrin-rich biofilm. In catheter infections in vivo, we could confirm that staphylokinase action reduces biofilm on foreign bodies. As such, while staphylocoagulase activity and fibrin are crucial for the primary adhesion and the establishment of an S. aureus biofilm, staphylokinase activity takes its role in the later stages of biofilm disassembly. (Chapter 2, Research Question 2)The manipulation of the fibrinolytic system by bacteria is a widespread phenomenon, which we have reviewed in Chapter 3. Plasminogen activation offers pathogens the opportunity to degrade fibrin, invade host tissues and evade immune attacks. To date, few therapeutic strategies have been derived from these observations. A first hypothetical option could be to use anti-proteases to limit unregulated proteolytic activity such as occurs in necrotizing fasciitis. We have studied a second option: using fibrinolytic coatings to prevent S. aureus device infections.Apart from its manipulation of the fibrinolytic system, S. aureus is notable for its interaction with coagulation factors. The contribution of S. aureus coagulase activity to outcome in different infection models, and the promising effects of coagulase inhibition are reviewed in Chapter 4. This provides a consistent preclinical evidence base to foster translational research of coagulase inhibition in a clinical trial.We have completed the first trial of coagulase inhibition in S. aureus bacteremia, in 94 patients collected over a 3-year period. Our results show that the feasibility of coagulase inhibition with available direct thrombin inhibitors is limited by their anticoagulant action. However, the observation of faster resolution of coagulation disturbances associated with S. aureus infection in patients treated with direct thrombin inhibitors, stimulates further research on specific inhibitors of bacterial coagulase activity that do not interfere with host thrombin. (Chapter 5, Research Question 3)In a final series of experiments, we have shown that the ratio between ADAMTS-13 and von Willebrand factor (VWF) modulates the course of S. aureus sepsis. Both high VWF levels and (relative) deficiency of ADAMTS-13 promote end organ microvascular thrombosis and mortality in S. aureus bloodstream infections. It remains to be shown if proteolysis of the ultra-long VWF that renders the inflamed vessel wall ‘ultra-adhesive’ for platelets and neutrophils, could improve outcome in S. aureus bacteremia. (Chapter 6, Research Question 4)In conclusion, we have gained further insight into the role of the hemostatic system in S. aureus infections. Our data could suggest future therapeutic endeavors to improve the management of these frequent and often difficult-to-treat infections. Some observations might be relevant and deserve exploration beyond S. aureus disease. For example, evaluation of the prevention of fibrin deposition on intravascular devices might also decrease other biofilm infections on these foreign bodies. Also, coagulation deregulation, and more specifically von Willebrand factor and the inflamed vessel wall, warrant further study as possible targets to mitigate the outcome of sepsis.
Choose an application
Choose an application
Listing 1 - 10 of 22 | << page >> |
Sort by
|